Avantor, Inc. $AVTR Position Cut by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its position in Avantor, Inc. (NYSE:AVTR) by 5.5% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,027,738 shares of the company’s stock after selling 118,991 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.30% of Avantor worth $20,075,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of Avantor during the second quarter valued at approximately $695,784,000. Wellington Management Group LLP bought a new stake in shares of Avantor in the 4th quarter worth $268,584,000. Engine Capital Management LP lifted its holdings in shares of Avantor by 65.8% in the first quarter. Engine Capital Management LP now owns 19,780,830 shares of the company’s stock valued at $155,082,000 after buying an additional 7,853,018 shares during the period. Barrow Hanley Mewhinney & Strauss LLC acquired a new stake in shares of Avantor in the second quarter valued at $195,386,000. Finally, Morgan Stanley boosted its stake in Avantor by 179.4% during the fourth quarter. Morgan Stanley now owns 17,468,418 shares of the company’s stock valued at $200,188,000 after buying an additional 11,216,565 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently commented on AVTR shares. Barclays boosted their target price on shares of Avantor from $7.00 to $8.00 and gave the stock an “underweight” rating in a report on Wednesday, June 24th. TD Cowen restated a “hold” rating on shares of Avantor in a research report on Wednesday, July 15th. Wall Street Zen raised Avantor from a “hold” rating to a “buy” rating in a report on Saturday, June 27th. Royal Bank Of Canada increased their price objective on Avantor from $9.00 to $14.00 and gave the company a “sector perform” rating in a research report on Thursday, July 30th. Finally, Wolfe Research raised Avantor from a “strong sell” rating to a “hold” rating in a research note on Thursday, July 30th. Two investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $12.00.

Avantor Price Performance

NYSE AVTR opened at $14.96 on Friday. The company has a quick ratio of 1.18, a current ratio of 1.78 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $10.12 billion, a PE ratio of -17.81, a price-to-earnings-growth ratio of 11.46 and a beta of 0.89. Avantor, Inc. has a 12-month low of $7.26 and a 12-month high of $15.93. The company has a 50 day moving average price of $12.62 and a two-hundred day moving average price of $9.93.

Avantor (NYSE:AVTR) last announced its quarterly earnings results on Wednesday, July 29th. The company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.02. The company had revenue of $1.69 billion during the quarter, compared to analysts’ expectations of $1.61 billion. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%.The business’s quarterly revenue was up .5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.24 earnings per share. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. As a group, equities analysts predict that Avantor, Inc. will post 0.81 earnings per share for the current fiscal year.

Avantor Company Profile

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.